56
Participants
Start Date
May 31, 2013
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
Placebo
Placebo infusion
ABT-719
Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
Site Reference ID/Investigator# 105756, Odense C
Site Reference ID/Investigator# 105757, Kolding
Site Reference ID/Investigator# 105755, Aarhus N
Site Reference ID/Investigator# 96996, New York
Site Reference ID/Investigator# 97556, Pittsburgh
Site Reference ID/Investigator# 108255, Charlottesville
Site Reference ID/Investigator# 96296, Durham
Site Reference ID/Investigator# 96778, Jacksonville
Site Reference ID/Investigator# 96295, Gainesville
Site Reference ID/Investigator# 96301, Tampa
Site Reference ID/Investigator# 102019, Memphis
Site Reference ID/Investigator# 103355, Columbus
Site Reference ID/Investigator# 102020, Cleveland
Site Reference ID/Investigator# 101961, Indianapolis
Site Reference ID/Investigator# 96302, Fort Wayne
Site Reference ID/Investigator# 99377, Royal Oak
Site Reference ID/Investigator# 96997, Grand Blanc
Site Reference ID/Investigator# 97878, Petoskey
Site Reference ID/Investigator# 96300, Milwaukee
Site Reference ID/Investigator# 103356, Boston
Site Reference ID/Investigator# 96303, Boston
Site Reference ID/Investigator# 99317, West Orange
Site Reference ID/Investigator# 103316, Providence
Lead Sponsor
AbbVie
INDUSTRY